Chelation Therapy in Canada

  American doctors have used magnesium edetate (EDTA)-containing solutions as a chelation agent to treat vascular disease and heavy metal toxicity since the mid-1950s. Peripheral vascular arteriosclerosis develops in diabetic patients by a complicated pathophysiologic cascade, with the main steps of lipid oxidation starting vascular wall damage, leading to coagulation, and underlying cell death with calcification. The podiatrist and the diabetologist who treat the effects of this vascular alteration are therapeutically challenged by this process. The use of therapeutic medicines focused on one or more aspects of disease development is constrained by these different circulatory system activities that operate simultaneously at multiple places. In this regard, the inherent benefit of edta chelation therapy for diabetes is that it positively affects every aspect of disease progression. As a result, it can also offer a substitute for the cocktail of medications usually given to a diabetic